{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:38:17Z","timestamp":1792579097463,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) diagnosis relies on PSA testing, but its low specificity leads to overdiagnosis. Stockholm3 may improve diagnostic accuracy. This study evaluated the performance of Stockholm3 for detecting clinically significant PCa (csPCa), defined as ISUP grade\u2009\u2265\u20092 on biopsy, in a real-world, non-referral Swiss cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of a prospective registry (2023\u20132025) at a non-referral urology practice in Switzerland. Initial screening was performed in men with PSA\u2009&gt;\u20091.5 ng\/mL or a suspicious digital rectal examination. Patients who underwent Stockholm3 and biopsy were included. We compared Stockholm3 with PSA, PSA density, and the SWOP risk calculator for the detection of csPCa in a pre-MRI diagnostic setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 178 men (median age 65 years, IQR: 60.0\u201370.0). Among them, 60\/178 (33.7%) had csPCa. Stockholm3\u2009\u2265\u200915 showed sensitivity 0.78 (95% CI 0.67\u20130.88), specificity 0.44 (95% CI 0.35\u20130.54), and AUC 0.68 (95% CI 0.60\u20130.77). SWOP score\u2009&gt;\u20094% showed sensitivity 0.42 (95% CI 0.30\u20130.55), specificity 0.78 (95% CI 0.70\u20130.85), and AUC 0.68 (95% CI 0.59\u20130.76). Both tests outperformed PSA\u2009&gt;\u20093 ng\/mL and PSA density\u2009&gt;\u20090.15 ng\/mL\u00b2, with AUCs of 0.52 (95% CI 0.48\u20130.56) and 0.57 (95% CI 0.50\u20130.64), respectively. Decision curve analysis and calibration curves favored Stockholm3 over SWOP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a non-referral setting, Stockholm3 confirmed good diagnostic performance for csPCa. These findings support its use as part of the primary diagnostic work-up in similar clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06377-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:03:03Z","timestamp":1774458183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of Stockholm3 for prostate cancer detection in a swiss non-referral cohort: balancing biopsy reduction and diagnostic performance"],"prefix":"10.1007","volume":"44","author":[{"given":"Jonas","family":"Mudlagk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Minder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Mortezavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bulling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Mordasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9844-1799","authenticated-orcid":false,"given":"Nicola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"6377_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005","journal-title":"Eur Urol"},{"key":"6377_CR2","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A et al (2018) Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362:k3519. https:\/\/doi.org\/10.1136\/bmj.k3519","journal-title":"BMJ"},{"issue":"11","key":"6377_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.2014.2085","volume":"311","author":"JH Hayes","year":"2014","unstructured":"Hayes JH, Barry MJ (2014) Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 311(11):1143\u20131149. https:\/\/doi.org\/10.1001\/jama.2014.2085","journal-title":"JAMA"},{"issue":"16","key":"6377_CR4","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gronberg","year":"2015","unstructured":"Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y et al (2015) Prostate cancer screening in men aged 50\u201369 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol 16(16):1667\u20131676. https:\/\/doi.org\/10.1016\/S1470-2045(15)00361-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"6377_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.eururo.2021.12.021","volume":"82","author":"S Hao","year":"2022","unstructured":"Hao S, Heintz E, Ostensson E, Discacciati A, Jaderling F, Gronberg H et al (2022) Cost-effectiveness of the Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. Eur Urol 82(1):12\u201319. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.021","journal-title":"Eur Urol"},{"issue":"4","key":"6377_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.euf.2023.09.016","volume":"10","author":"A Elyan","year":"2024","unstructured":"Elyan A, Saba K, Sigle A, Wetterauer C, Engesser C, Puschel H et al (2024) Prospective multicenter validation of the Stockholm3 test in a central European cohort. Eur Urol Focus 10(4):620\u2013626. https:\/\/doi.org\/10.1016\/j.euf.2023.09.016","journal-title":"Eur Urol Focus"},{"issue":"9","key":"6377_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstrom","year":"2021","unstructured":"Nordstrom T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M et al (2021) Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol 22(9):1240\u20131249. https:\/\/doi.org\/10.1016\/S1470-2045(21)00348-X","journal-title":"Lancet Oncol"},{"issue":"1","key":"6377_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.euf.2024.07.009","volume":"11","author":"D Tilki","year":"2025","unstructured":"Tilki D, Rejek N, Nohe F, Haese A, Graefen M, Thederan I (2025) External validation of Stockholm3 in a Retrospective German Clinical Cohort. Eur Urol Focus 11(1):82\u201387. https:\/\/doi.org\/10.1016\/j.euf.2024.07.009","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6377_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eururo.2009.08.025","volume":"57","author":"MJ Roobol","year":"2010","unstructured":"Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH et al (2010) A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 57(1):79\u201385. https:\/\/doi.org\/10.1016\/j.eururo.2009.08.025","journal-title":"Eur Urol"},{"issue":"2","key":"6377_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.euf.2016.07.007","volume":"4","author":"M Gayet","year":"2018","unstructured":"Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA et al (2018) Prediction of prostate cancer: external validation of the ERSPC risk calculator in a contemporary dutch clinical cohort. Eur Urol Focus 4(2):228\u2013234. https:\/\/doi.org\/10.1016\/j.euf.2016.07.007","journal-title":"Eur Urol Focus"},{"issue":"3","key":"6377_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.euf.2022.11.021","volume":"9","author":"T Palsdottir","year":"2023","unstructured":"Palsdottir T, Gronberg H, Hilmisson A, Eklund M, Nordstrom T, Vigneswaran HT (2023) External validation of the rotterdam prostate cancer risk calculator and comparison with Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort. Eur Urol Focus 9(3):455\u2013462. https:\/\/doi.org\/10.1016\/j.euf.2022.11.021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6377_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00345-022-04185-y","volume":"41","author":"MJ Hagens","year":"2023","unstructured":"Hagens MJ, Stelwagen PJ, Veerman H, Rynja SP, Smeenge M, van der Noort V et al (2023) External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort. World J Urol 41(1):13\u201318. https:\/\/doi.org\/10.1007\/s00345-022-04185-y","journal-title":"World J Urol"},{"key":"6377_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2021.11.002","volume":"36","author":"S Remmers","year":"2022","unstructured":"Remmers S, Kasivisvanathan V, Verbeek JFM, Moore CM, Roobol MJ, Group ERSGPI (2022) Reducing biopsies and magnetic resonance imaging scans during the diagnostic pathway of prostate cancer: applying the Rotterdam Prostate Cancer risk calculator to the PRECISION trial data. Eur Urol Open Sci 36:1\u20138. https:\/\/doi.org\/10.1016\/j.euros.2021.11.002","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"6377_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1353\/hpu.0.0253","volume":"21","author":"NM Marlow","year":"2010","unstructured":"Marlow NM, Halpern MT, Pavluck AL, Ward EM, Chen AY (2010) Disparities associated with advanced prostate cancer stage at diagnosis. J Health Care Poor Underserved 21(1):112\u2013131. https:\/\/doi.org\/10.1353\/hpu.0.0253","journal-title":"J Health Care Poor Underserved"},{"issue":"1","key":"6377_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tau.2017.12.21","volume":"7","author":"N Pereira-Azevedo","year":"2018","unstructured":"Pereira-Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ (2018) Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. Transl Androl Urol 7(1):18\u201326. https:\/\/doi.org\/10.21037\/tau.2017.12.21","journal-title":"Transl Androl Urol"},{"issue":"2","key":"6377_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"issue":"3","key":"6377_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","volume":"6","author":"M Maggi","year":"2020","unstructured":"Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G et al (2020) Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 6(3):463\u2013478. https:\/\/doi.org\/10.1016\/j.euf.2019.06.014","journal-title":"Eur Urol Focus"},{"key":"6377_CR18","doi-asserted-by":"publisher","unstructured":"Nguyen TA, Fourcade A, Zambon A, Saout K, Deruelle C, Joulin V et al (2023) Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI. Urol Oncol 41(8):354 e11- e18. https:\/\/doi.org\/10.1016\/j.urolonc.2023.05.005","DOI":"10.1016\/j.urolonc.2023.05.005"},{"issue":"6","key":"6377_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1590\/s1677-55382004000600003","volume":"30","author":"WC Cheng","year":"2004","unstructured":"Cheng WC, Ng FC, Chan KC, Cheung YH, Chan WL, Wong SW (2004) Interobserver variation of prostatic volume estimation with digital rectal examination by urological staffs with different experiences. Int Braz J Urol 30(6):466\u2013471. https:\/\/doi.org\/10.1590\/s1677-55382004000600003","journal-title":"Int Braz J Urol"},{"issue":"9","key":"6377_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pros.20759","volume":"68","author":"C Gosselaar","year":"2008","unstructured":"Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schroder FH (2008) The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68(9):985\u2013993. https:\/\/doi.org\/10.1002\/pros.20759","journal-title":"Prostate"},{"issue":"32","key":"6377_CR21","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1200\/JCO.24.00152","volume":"42","author":"HT Vigneswaran","year":"2024","unstructured":"Vigneswaran HT, Eklund M, Discacciati A, Nordstrom T, Hubbard RA, Perlis N et al (2024) Stockholm3 in a multiethnic cohort for prostate cancer detection (SEPTA): a prospective multicentered trial. J Clin Oncol 42(32):3806\u20133816. https:\/\/doi.org\/10.1200\/JCO.24.00152","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06377-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06377-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06377-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:41:28Z","timestamp":1792575688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06377-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6377"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06377-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Cantonal Ethics Committee of Zurich, Switzerland (BASEC-Nr. Req-2025-00421). The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, and informed consent was obtained for all patients.","order":2,"name":"Ethics","label":"Compliance with ethical declarations","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"268"}}